FDA Takes “Property”-Based Approach To Nanotech, Raises Roof To 1 Micron
This article was originally published in The Rose Sheet
Executive Summary
In its newly released guidance to industry, FDA indicates that “agglomerates and aggregates” of materials that exceed the oft-cited ceiling of 100 nanometers may still warrant consideration as nanotechnology based on their “properties,” a position that could impact the cosmetics sector.
You may also be interested in...
In Nanotech Metrics, Safety Should Trump Size, Experts Say
Evaluations of novel products based on nanotechnology should focus on safety and efficacy more than particle size, presenters at the FDLI annual conference say. The Project on Emerging Nanotechnologies is updating its product inventory to include more nanomaterial safety data.
Congress Instructs FDA On Nanotech Work, But Mute On Funding
Newly passed user-fee legislation includes a provision directing FDA to intensify its research and policy development regarding nanotechnology and its use in consumer products. How such efforts are to be funded remains a question.
Nanotech Is “More Than Just Tiny,” Requires FDA Regulation – Lawsuit
A suit filed in U.S. District Court Dec. 21 by coalition of advocacy groups says FDA's failure to respond "meaningfully" to 2006 citizen petition on nanotechnology violates federal law. Lawsuit asks court to order FDA to respond to their peititon without further delay.